statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for TARS
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021OppenheimerInitiates Coverage OnOutperform Oct 2021Raymond JamesMaintainsStrong Buy...

Analyst Ratings For Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $48.38 Average PT from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) General Counsel Bryan Wahl sold 4,436 shares of the firms stock in a transaction dated Monday, March 18th. The stock was sold...

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $135,741.60 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) COO Seshadri Neervannan sold 4,879 shares of the companys stock in a transaction dated Monday, March 18th. The shares were...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) COO Sells $149,297.40 in Stock

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) rose 6.9% on Friday . The stock traded as high as $31.73 and last traded at $31.47. Approximately 103,785 shares changed...

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.9%

This indicator may be signaling that TARS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Tarsus Pharmaceuticals (TARS, $30.5) entered Downtrend as Momentum indicator drops below 0 level on Mar 11, 2024

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name...

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...

Tarsus to Participate at Upcoming Investor Conferences

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tarsus Pharmaceuticals introduces 'Mite Party' marketing campaign

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately...

Tarsus Introduces  Mite Party  Campaign for XDEMVY  (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Watchers	409
52-Wk Low	$12.57
52-Wk High	$42.50

Volume	314,731.00
52-Wk High	$42.50
52-Wk Low	$12.57

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.93	--	--	N/A
Q1'24	-$1.18	-$1.01	14.47%	BEAT
Q4'23	-$1.37	-$1.31	4.53%	BEAT
Q3'23	-$1.35	-$1.28	5.22%	BEAT
Q2'23	-$1.08	-$1.17	-8.44%	MISSED

TARS Tarsus Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals